# InfuSystem Holdings share price today (InfuSystem Holdings, Inc., INFU)

> InfuSystem Holdings, Inc.'s earnings have grown faster than its share price. Earnings per share grew +181.8% in a year while the price moved +23.6%. INFU · Healthcare · Medical Devices · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/infu

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from the last 12 quarters
- Price: $12.80 (+23.6% in a year)
- P/E: 31.9× (higher than 60% of the last 1 year)
- Revenue (Jun 2026): $36.9 M (+2.6% on a year ago)
- Profit (Jun 2026): $3.2 M (+24.3% on a year ago)
- Operating margin: 11.2% (+0.7 points on a year ago)
- ROE: 12%, FY25
- ROIC: 9.6%, against a 11.6% cost of capital: −2.0 points

The main question: yearly earnings per share moved +181.8% while the share price moved +23.6%. ## What is the InfuSystem Holdings share price today? InfuSystem Holdings, Inc.'s share price was $12.80 at the close on 3 November 2026. That is 23.3% above its average price over the last 200 trading days. In the last 52 weeks it traded between $8 and $14, and at that close it sat 81% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 14 weeks in a row. Over the last 1 year the share price moved +121% while the S&P 500 moved +21%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does InfuSystem Holdings pay? InfuSystem Holdings, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is InfuSystem Holdings on? InfuSystem Holdings is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is InfuSystem Holdings profitable? InfuSystem Holdings, Inc. earned $3.2 M of net profit in the Jun 2026 quarter, +24.3% on the same quarter a year earlier. Full-year FY25 profit was $6.6 M. Over 4 years profit has grown 47.0% a year on average. That is 8.7% of the quarter's revenue. The same quarter a year earlier earned $2.6 M. 2 of the last 12 reported quarters were loss-making. For the full year, FY25 profit was $6.6 M (+182.6% on the year before). Why profit moved: revenue changed +2.6% on a year earlier and the margin moved +0.7 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +55.8% and revenue +2.5%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit. ## How much revenue does InfuSystem Holdings make, and is it growing? InfuSystem Holdings, Inc. reported $36.9 M of revenue in the Jun 2026 quarter, +2.6% on the same quarter a year earlier. Over 4 years it has grown 8.8% a year on average. The last full year, FY25, came in at $143 M. The last four reported quarters add to $143 M. FY25 revenue was $143 M, +6.4% on the year before. Recent pace: the last four quarters grew +2.5% on average, against 8.8% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +2.5%, against +5.3% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +68.4%, against +383.1% a year (rolling over). ## How much of every $100 of sales does InfuSystem Holdings keep? InfuSystem Holdings, Inc.'s operating margin was 11.2% in the Jun 2026 quarter, 0.7 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between 1.5% and 7.6%. The latest quarter is above every full year in that period. Across 5 years it has been between 1.5% and 7.6%, and FY25's 7.6% is the highest of them. Why the margin moved: operating margin changed +0.7 percentage points on the year while gross margin changed +2.8 points. So the gain came mostly from the gross margin, which means input costs and prices charged. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is InfuSystem Holdings' profit turning into cash? Over the last 3 years, 570% of InfuSystem Holdings, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $24.4 M of operating cash against $6.6 M of profit. After $8.7 M of spending on assets, $15.7 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does InfuSystem Holdings' cash go? InfuSystem Holdings, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $37.6 M on assets over the last 3 years. Averaged over those years that is 8.7% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $37.6 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is InfuSystem Holdings' P/E ratio, and how does it compare with its own history? InfuSystem Holdings, Inc.'s P/E is 31.9×, in the middle of its own history: higher than 60% of past readings. Its usual P/E (the middle reading) is 30.5×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +181.8% while the price moved +23.6%. Earnings did better than the price, which pulled the multiple down within its own range. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the InfuSystem Holdings business getting better or worse? InfuSystem Holdings, Inc.'s business is giving mixed signals. Growth is slowing from a very fast pace: profit growth has eased from +1285.8% at its peak to +68.4%, but the business is still expanding, with ROCE rising at 13.5%. This is based on 12 quarters of 4 measures. Why it matters: when the lines disagree, each line above matters more than any single label. ## How much does InfuSystem Holdings earn on its capital? InfuSystem Holdings, Inc. earned a ROE of 12% in FY25. That is up from a low of 0% in FY22. Its return on capital used (ROIC) is 2.0 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 4.6% net margin and 1.43× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 4.6% net margin × 1.43× asset turnover × 1.75× leverage (assets divided by equity) ≈ 11.5% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 9.6% − 11.6% = −2.0 percentage points. The 11.6% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 9.6% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 8.3%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does InfuSystem Holdings have too much debt? InfuSystem Holdings, Inc. has total debt of $24.5 M against shareholder equity of $59.1 M as of Jun 2026, so its debt is 0.41× its equity. Year by year, that ratio went from 0.76 in FY21 to 0.43 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the InfuSystem Holdings shareholding pattern? 4.3% of InfuSystem Holdings, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 6.1 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is InfuSystem Holdings from balance-sheet trouble? For InfuSystem Holdings, Inc., the Z-score is 4.11. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 4.11 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does InfuSystem Holdings rank in its industry? There is no score against its industry: InfuSystem Holdings, Inc. is not among the largest members shown in this industry comparison for Medical Devices. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is InfuSystem Holdings compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to InfuSystem Holdings in size? InfuSystem Holdings is the 69th largest of 75 Medical Devices companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Quantum-Si incorporated, Treace Medical Concepts, Inc. and Profound Medical Corp. Just below it: Standard BioTools Inc., Electromed, Inc. and TriSalus Life Sciences, Inc. ### Medical Devices companies close in size

1. [Quantum-Si incorporated](https://www.sectoralpha.in/us/stocks/qsi) $285 million
2. [Treace Medical Concepts, Inc.](https://www.sectoralpha.in/us/stocks/tmci) $278 million
3. [Profound Medical Corp.](https://www.sectoralpha.in/us/stocks/prof) $255 million
4. InfuSystem Holdings, Inc. $255 million
5. [Standard BioTools Inc.](https://www.sectoralpha.in/us/stocks/lab) $240 million
6. [Electromed, Inc.](https://www.sectoralpha.in/us/stocks/elmd) $221 million
7. [TriSalus Life Sciences, Inc.](https://www.sectoralpha.in/us/stocks/tlsi) $214 million

[All 75 Medical Devices companies, largest first](https://www.sectoralpha.in/us/sectors/medical-devices#all-companies)

### Companies close in size in other industries

1. [Nano Dimension Ltd.](https://www.sectoralpha.in/us/stocks/nndm) $280 million · Computer Hardware
2. [Anika Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/anik) $280 million · Drug Manufacturers - Specialty & Generic
3. InfuSystem Holdings, Inc. $280 million
4. [Virginia National Bankshares Corporation](https://www.sectoralpha.in/us/stocks/vabk) $280 million · Banks - Regional
5. [High Templar Tech Limited](https://www.sectoralpha.in/us/stocks/htt) $280 million · Credit Services

## What else do people ask about InfuSystem Holdings? ### What were InfuSystem Holdings's latest quarterly results? InfuSystem Holdings, Inc. reported revenue of $36.9 M and net profit of $3.2 M for the Jun 2026 quarter. Revenue rose 2.6% and profit rose 24.3% compared with a year earlier. Earnings per share were $0.15. The operating margin was 11.2%, 0.7 percentage points higher than a year earlier (as of 3 November 2026). ### What is InfuSystem Holdings's market cap? InfuSystem Holdings, Inc.'s market capitalisation is $255 M at a stock price of $12.80. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is InfuSystem Holdings performing? InfuSystem Holdings, Inc.'s latest readings are below. In its latest quarter, revenue rose 2.6% and profit rose 24.3% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 14 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will InfuSystem Holdings's stock price go up? This page does not forecast InfuSystem Holdings, Inc.'s stock price. What it shows instead: the stock price is $12.80. Its P/E of 31.9× is higher than 60% of its own last 1 years. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Is InfuSystem Holdings's profit real cash? Yes, over the last 3 years, 570% of InfuSystem Holdings, Inc.'s reported profit came in as cash from operations. The latest year was lower at 368%, so the trend is worth watching. In FY25, operating cash was $24.4 M against reported profit of $6.6 M. Most of that cash then goes into building new capacity. These are yearly figures (as of 3 November 2026). ### Where is InfuSystem Holdings in its business cycle? InfuSystem Holdings, Inc.'s FY25 operating margin was 7.6%, against a 5-year range of 1.5% to 7.6%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 11.2%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the InfuSystem Holdings story? The main question: yearly earnings per share moved +181.8% while the share price moved +23.6%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is InfuSystem Holdings a stock worth studying right now? What the numbers show: InfuSystem Holdings, Inc.'s earnings have grown faster than its share price. Earnings per share grew +181.8% in a year while the price moved +23.6%. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.